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The effort and cost of obtaining neurons for large-scale screens has limited drug discovery in neuroscience.
To overcome these obstacles, we fabricated arrays of releasable polystyrene micro-rafts to generate
thousands of uniform, mobile neuron mini-cultures. These mini-cultures sustain synaptically-active
neurons which can be easily transferred, thus increasing screening throughput by .30-fold. Compared to
conventional methods, micro-raft cultures exhibited significantly improved neuronal viability and
sample-to-sample consistency. We validated the screening utility of these mini-cultures for both mouse
neurons and human induced pluripotent stem cell-derived neurons by successfully detecting disease-related
defects in synaptic transmission and identifying candidate small molecule therapeutics. This affordable
high-throughput approach has the potential to transform drug discovery in neuroscience.
L
arge-scale in vitro screening techniques have helped to advance basic research and identify numerous drugs
and drug candidates for treating human diseases, particularly in the field of oncology1–7. Unfortunately,
current methodologies are optimized for dividing cells that can be expanded to generate large sample sizes
and not for post-mitotic cells such as neurons. The high cell densities required for proper functional network
development have traditionally required the use of large numbers of neurons–up to 70,000 neurons/screen in a
384-well plate8. Furthermore, well-plates with smaller well volumes are not compatible with long-term cultures
due to evaporative effects9. Neurons from transgenic disease-model animals or differentiated from patient-
derived induced pluripotent stem cells (iPSCs) are available in limited quantities; obtaining sufficient neurons
for large-scale screens has been impractical. Thus, despite available sources of neurons that model human
neurological disease, large-scale screening studies in neurons remain rare and costly. With the goal of improving
the pace of neuronal drug discovery efforts, here we provide an affordable approach to enable high-throughput
screening in either rodent neurons or in human iPSC-neurons.
Results
Plating, release, and transfer of micro-rafts. We wanted to limit the number of neurons for each culture well, as
this would allow many more neuronal culture wells to be generated and screened from an initial pool of neurons.
At the same time, we sought to culture neurons at a sufficiently high density to promote synaptic connectivity and
neuronal maturation. It is not feasible to use higher density well-plates, such as the 1,536-well format, because of
detrimental evaporative losses due to the high surface area-to-volume ratio present in these minute well volumes.
Our approach to increase samples size with limited material was to use microfabricated raft arrays10 (movie S1).
We hypothesized that this technology would create cultures with sufficient neuronal density for network
maturation as well as minimal, yet effective, numbers of neurons for compound screening.
Each raft array consists of 1,600 releasable, polystyrene, ferromagnetic rafts (500 mm x 500 mm x 100 mm) cast
in a flexible poly(dimethylsiloxane) (PDMS) matrix and housed within a fluid reservoir suitable for holding cell
culture media (Fig. 1A–B). Rather than plating each surface individually as done in well-plates, approximately one
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raft), and after one to two days the rafts are released, en masse, into
cell culture media reservoirs where they are cultured together for
days or weeks to attain proper maturity with negligible evaporative
losses (Fig. 1C-E). Rafts are then sorted as needed into high content
well plates for compound screening via pipette and used for treat-
ment or staining. Alternatively, rafts can be transferred via a mag-
netic wand11. A magnetic plate placed under the well plate quickly
directs the magnetic raft to the bottom of the well. Importantly, once
rafts are located to the floor of the well, they stay in place during
normal transport or automated stage movements. The localization of
these rafts at the bottom of the well also allows for imaging via high
resolution microscopy and makes the rafts compatible with auto-
focus functions. To facilitate fluid exchanges and treatment proto-
cols, rafts are held in place on the well floor with a plate magnet. The
slight concavity of the raft (Fig. 1D) and the surface tension of the
media surrounding the raft protect neurons during release and trans-
fer, without compromising the high-content imaging required for
most screening strategies. Unlike contact spotting, which has been
used to generate small-sized cultures for non-neuronal cell types12–14,
the mobile raft mini-cultures can be independently screened in par-
allel. This method increases screening potential .30-fold over tra-
ditional well-plate cultures, while remaining compatible with well-
plate-based high-throughput drug screening equipment (Fig. 1F).
Mobile mini-cultures of human stem cell-neurons. Advances in
stem cell technology now allow generation of unprecedented
models of human neurological disease states in vitro; however, the
time and resources for such stem cell work presents a notable
bottleneck. We reasoned that our micro-raft approach might allow
screens using neurons derived from stem cells. We first generated
neurons from H9 embryonic stem cells (ESC-neurons; Fig. 2A–
E)15,16. We then cultured ESC-neurons onto raft arrays and
released rafts within 2 days (see Fig. 1D). Neuronal marker
expression and function (Fig. 2F–H) were confirmed by 5 days on
released rafts, further validating that the raft micro-cultures remain
functional after they are released from arrays.
Mini-cultures versus well-plate cultures. To evaluate the utility of
raft micro-cultures for drug screening, we performed a viability assay
using human ESC-neurons on released rafts compared with 384-well
plates (Fig. 3). We assessed the neuronal viability of our ESC-neurons
by determining the percentage of the dead cell marker SYTOX
green17 –positive cells and using nuclear markers (DAPI or
Hoechst) to label all cells (Fig. 3A). ESC-neurons were plated into
a 384-well plate at 20,000 neurons/well (initial plating density:
1,800 neurons/mm2), as performed previously18. Within the wells
of the well-plate, neurons are unevenly distributed, with the
highest density around the periphery. We chose to compare
neuron viabilities on day 5, the earliest time point we could detect
neuronal function (Fig. 2H) from 300 mm x 300 mm regions around
the center of each raft or well to simulate future automated imaging.
By this day, there was a significantly lower fraction of dead cells on
rafts than in wells (Fig. 3B). To ensure that the difference in viability
was not due to the difference in neuron density at this time
[612.5632.5 live neurons/mm2 on raft vs. 291.4621.9 live
neurons/mm2 in wells; p,0.001], we compared the percentage of
SYTOX1 neurons within a subset of rafts and wells containing
equivalent densities of live neurons (see methods; Fig. 3B). Within
these subsets, the difference in neuronal viability was retained (p ,
0.05).
Next, we quantified sample-to-sample variability by plotting the
percentages of SYTOX1 neurons of either rafts or wells on day 5
(Fig. 3C). Our analysis suggests that the percentage of dead cells is
more consistent between rafts than between wells. Indeed, the cumu-
lative distributions of percentages of SYTOX1 neurons were signifi-
cantly different, with the distribution for the rafts significantly
steeper, indicating less variability between rafts compared with wells
(p,0.05). In addition, the between-sample consistency was main-
tained using rafts up to day 14 (Fig. 3C–D), whereas neurons in wells
required daily media changes to survive (data not shown). This lack
of maintenance requirements for raft arrays is a significant advantage
over high-density well plates. These differences could be due to the
higher amount of neuronal material required for well plating more
quickly depleted the media of nutrients. Using rafts would drastically
decrease the number of neurons per screen. Alternatively, over this
time media composition in small volume well plates might be sig-
nificantly altered by evaporation. Released rafts can be maintained in
larger volume reservoirs of media less sensitive to evaporative effects
and later moved to high content plates for imaging. Taken together,
the increases in both neuronal viability and sample-to-sample repro-
Figure 1 | Each micro-raft array can generate thousands of separate and
mobile neuron mini-cultures, including neuron cultures differentiated
from human embryonic stem cells (ESCs). (A) Photograph of the
micro-raft array and housing. Each array has 1,600 releasable rafts
embedded in a flexible PDMS matrix. (B) A higher magnification image of
microraft array (each raft is 500 mm x 500 mm) within the PDMS matrix,
prior to release. (C) Cartoon depiction of raft release using a blunt probe to
deflect the PDMS matrix, releasing the rigid polystyrene raft mini-cultures
into the media. (D) DIC image of a representative raft micro-culture
containing human ESC-neurons, released from the array at day 1 and
grown on a released raft for an additional 18 days. Scale bar, 150 mm. (E)
zoom of dashed box in (D) stained with live cell dye, Celltracker AM. Scale
bar, 50 mm. (F) Micro-raft arrays increase screening potential .30-fold
compared to using well-plates directly.
www.nature.com/scientificreports
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ducibility represent distinct advantages of raft arrays over conven-
tional well-plate cultures.
Measurement of synaptic phenotypes using human iPSC-neurons.
While sample-to-sample consistency between screens is vital to drug
discovery, it is also critical that the model system recapitulates
human disease phenotypes9. Often this is accomplished by
harvesting neurons from readily-available transgenic rodent lines,
but human iPSCs are increasingly used to generate neurons from
neurological patients. To confirm that raft mini-cultures could
successfully be used as a platform to model human disease
phenotypes, we used iPSC-neurons from a patient with Fragile X
(FX iPSC-neurons), the most prevalent inherited form of intellectual
disability19, and we functionally compared these neurons to iPSC-
neurons from a neurotypical individual (CNTL iPSC-neurons)
(Fig. 4A–H). We concentrated on FX for these proof-of-principle
experiments because: 1) the genes underlying FX are well-known, 2)
the disease state can be confirmed by the lack of Fragile X mental
retardation protein (FMRP) expression, and 3) there is a well-
characterized, transgenic rodent model (the FMR1 KO mouse) for
comparison. Importantly, iPSC-neurons exhibited neuronal markers
(Fig. 4C), and neither the reprogramming nor differentiation altered
the level of FMRP expression (Fig. 4D).
We plated FX and CNTL iPSC-neurons onto raft arrays, released
them after 1 day, and then used lipophilic FM dyes to evaluate differ-
ences in presynaptic function at 14 days post-plating20,21. We found a
significant decrease in the volume of FM puncta following activity-
dependent loading in FX iPSC-neurons, compared to CNTL-iPSC
neurons (Fig. 4E), suggesting a smaller recycling pool or a reduction
in the rate of endocytosis. In addition, we found significantly
enhanced unloading kinetics in FX iPSC-neurons, compared to
CNTL iPSC-neurons (Fig. 4F–H). Importantly, these differences
were also found between primary neurons from FMR1 KO mice
and WT mice (Fig. 4E–H), and are consistent with the previous find-
ings that FX neurons have decreased numbers of synaptic vesicles22
and a higher probability of neurotransmitter release23. These results
demonstrate that, despite the reduced number of neurons in micro-
rafts compared to culture-wells, there remains sufficient statistical
power to screen and identify reproducible functional phenotypes.
Drug screening using released micro-rafts. Finally, we performed a
proof-of-concept study to demonstrate the use of raft arrays in a drug
screening assay, by reproducing previous results from a much lower
throughput screen18. We used embryonic neurons from a mouse
model containing a Ube3a-YFP transgene within the normally
silent paternal allele previously used to screen potential therapeutic
Figure 2 | Human ESC cells differentiate into glutamatergic neurons. (A) Schematic of the stem cell neuron differentiation protocol. Days are
numbered 0–24 for neuronal differentiation into neural progenitor cells, and then renumbered following final plating during neuronal maturation
(see methods for details). Solution was replaced every day with the appropriate media plus factors listed above. Vertical, dashed lines indicate cellular
plating; the red line indicates final plating into raft arrays or well plates. Representative micrographs of cells during (B) maintenance, (C) differentiation
(day 10), and (D, E) maturation (day 1 and 10, respectively). Scale bars, 100 mm. (F) Mature, stem cell-neurons were MAP2-positive and (G) exhibited
robust VGLUT1 expression on released rafts. (H) To test for functional activity-dependent synaptic vesicle release in stem cell-neurons, presynaptic
terminals were loaded with FM dye (5–95) with KCl and unloaded with electrical stimulation (see methods for details), showing activity-dependent
synaptic vesicle release at day 5 on rafts. Scale bar, 10 mm.
www.nature.com/scientificreports
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compounds for Angelman syndrome18. Just as in the previous screen,
the topoisomerase inhibitor, topotecan, successfully increased
expression of YFP in raft mini-cultures (Fig. 5), indicating that
topotecan activates the normally dormant paternal allele of Ube3a.
Together, these data show that drug treatment in raft mini-cultures
reproduces findings reported using traditional well-plate cultures.
Discussion
Micro-raft arrays allow significantly enhanced sample sizes and a
reduction in the number of neurons needed from existing supply-
limited sources. An extraordinary amount of time and resources are
dedicated to generating neuron cultures. The lack of efficient differ-
entiation protocols for stem cells and the length of time required to
differentiate and maintain these neurons (.30 days), present bottle-
necks for their use in high-throughput screening9. For neurons
obtained directly from embryonic mice, which yield the largest num-
ber of live cortical neurons, the generation of animals presents a
major bottleneck, compounded by poor reproductive success
(,50%), small litter size, long gestation times, and short fertile win-
dows. For example, cortical neurons harvested from a single mouse
embryo (,3,000,000 neurons) could generate 4,800 rafts; the same
number of samples using 384-well-plates would require 32 embryos
and multiple litters.
Micro-raft arrays also overcome key technical challenges in high-
throughput screening using neurons. First, they overcome difficulties
with evaporation that plague traditional long-term micro-cultures in
high-density well plates9. After micro-rafts are released, they can be
cultured for extended lengths of time in large media volumes that are
not affected significantly by evaporation until they are ready to be
transferred for screening and imaging. Second, the use of arrays
reduces the plating time, supplies, and reagents, because dissociated
neurons are plated en masse onto each disposable array (,3 arrays
per embryonic mouse cortex) (movie S1).
Finally, additional experimental possibilities result from advan-
tages in handling capabilities. These arrays are produced rapidly and
reproducibly11, do not require large investment in expensive equip-
Figure 3 | Human ESC-neuron mini-cultures on released micro-rafts are more viable and consistent compared with 384-well-plate cultures. (A)
Example images of nuclei (DAPI, blue) and dead cells (SYTOX1, turquoise) from human ESC-neurons cultured for 5 days from the center of a well of a
384-well plate (top) and a released raft (bottom). Scale bar, 20 mm. (B) Graph showing the percentage of dead human ESC-neurons (SYTOX1/DAPI1)
in wells of a 384-well-plate after 5 days in vitro (d5) and raft-mini-cultures at d5 and d14. This graph also shows a subset analysis of raft and
well-plate cultures at d5 with equivalent cell densities. (C) Graph plot of all data points for wells and rafts shown in (B). (D) Normal cumulative
distributions plots of rafts and wells presented in (C). *p,0.05.
www.nature.com/scientificreports
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ment, and are compatible with existing high-throughput fluid hand-
ling equipment, established compound libraries, and high-resolution
fluorescence microscopy. The consistent boundaries of the raft will
facilitate automated detection for high-throughput imaging. Thus,
the raft arrays are well-suited for both basic science experimentation
and high-throughput screens. In summary, these data show that
micro-raft arrays can dramatically increase the scale of screening
studies in neurons and open up neuron-based large-scale screening
to the broad research community.
Methods
Stem Cells. The NIH-approved, human embryonic stem cell (ESC) line H9 (WA09)
was obtained from WiCell Research Institute (Madison, WI). H9 ESCs were
maintained as undifferentiated colonies on growth factor reduced Matrigel (BD
Biosciences) in mTeSR1 media (StemCell Technologies). Media was changed daily.
Cells were passaged every three days with 0.5 mM EDTA (340 mOs).
Human iPSCs were generated from purchased human fibroblast lines. The Fragile
X positive fibroblast line, GM05131A was purchased from Coriell Institute for
Medical Research at passage 11 and non-Fragile X line CCD-1079sk was obtained
from ATCC and used for experiments at passage 7. Both lines were maintained and
cultured according to the vendor’s instructions. To induce pluripotency, both
fibroblast lines were plated into 6-well plate (200,000 cells/well) and maintained
overnight in DMEM (Gibco) supplemented with 10% FBS (Gibco). Cells were then
infected with lentiviral particles carrying the following reprogramming genes: Oct4,
Figure 4 | Raft mini-cultures can be used for cell-based assays of autism-linked neurodevelopmental disorders using both human iPSC-neurons and
mouse model neurons. (A) Human iPSCs derived from fibroblasts of Fragile X or Control patients express the pluripotency marker Oct4 following
reprogramming. (B) Both iPSC lines, differentiated as embryoid bodies for 3 weeks, expressed nestin, smooth muscle actin (SMA) or alpha fetoprotein,
markers of ectoderm, mesoderm and endoderm, respectively. Scale bar, 50 mm. (C) Images of iPSC-neurons derived from FX individuals immunolabeled
for excitatory neuronal markers VGLUT1 (‘fire’ look up table key shown; green in merged image) and MAP2 (red). Scale bar, 10 mm. (D) Images
showing FMRP expression (red) of control and FX iPSC-neurons differentiated and grown on released rafts for 14 days (DAPI, blue). Scale bar, 10 mm.
(E) Graph of the average FM4-64 puncta volumes for human FX iPSC-neurons (hFX; n 5 477), control iPSC-neurons (hCNTL; n 5 196), mouse
FX hippocampal neurons (mFX; n 5 208), and mouse wild-type hippocampal neurons (mWT; n 5 165). (F) Graph of average percent unloading of FM5-
95 puncta after electrical stimulation for hFX (n 5 100), hCNTL (n 5 90), mFX (n 5 698), and mWT (n 5 461). (G) Unloading curves of mean
normalized fluorescence intensity of FM puncta over time (before and during stimulation) for hCNTL and hFX iPSC-neurons. (H) Bar graph of the mean
fluorescence decay constant, t, for FM puncta in response to electrical stimulation for both human and mouse Fragile X cellular models and controls;
samples size are described in (F). *p,0.05.
Figure 5 | Topotecan induced the unsilencing of Ube3a-YFP
(immunolabeled using an anti-GFP antibody, green) expressed on the
normally silent paternal allele in mouse cortical neurons mini-cultures
grown on rafts. 300 nM Topotecan, 72 hours. Scale bar, 100 mm.
www.nature.com/scientificreports
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Sox2, Klf4, cMyc, Lin28 and Nanog. Individual hiPS clones were selected after 14 to 21
days, expanded and characterized using the germ layer characterization kit
(Millipore). To verify their pluripotency hiPS clones were plated onto 10 cm tissue
culture dishes and grown to 80% confluency. At this point cells were dissociated using
EDTA and grown for three weeks as embryoid bodies (EBs) in suspension on Petri
dishes in IMDM (Lonza) supplemented with 10% FBS (HyClone). In addition, Rock
inhibitor (Selleck Chemicals) was maintained in the medium for the first 24 hours.
After three weeks embryoid bodies were seeded on Matrigel-coated 6-well plates,
fixed and processed for expression of germ layer biomarkers (Fig. 2).
Differentiation and maintenance of human ESC- and iPSC-neurons. We adapted a
previously published protocol for physiologically-active, glutamatergic neurons of
the forebrain16. Stem cells were maintained and expanded in mTeSR1 for 1 week
(passaged on day 3 and 6) then dissociated to single cells using 0.5 mM EDTA
(340 mOs) and plated in suspension on Petri dishes in DMEM/F12 plus 20%
knockout serum replacement, 1 mM L-glutamine, 1% nonessential aminoacids and
0.1 mM beta-mercaptoethanol (EB media). EB media was half-changed daily.
Between days 1 and 5 of differentiation, media was supplemented with: SB431542
(10 mM), LDN193189 (100 nM), XAV939 (10 mM) and retinoid acid (10 mM). On
day 5 of differentiation the EBs (30-50/well) were seeded on 6-well Matrigel-coated
plates in N2B27 medium, consisting of a 151 mixture of N2 medium (DMEM/F12
GlutaMAX, 1 X N2, 5 ug/ml insulin, 1 mM L-glutamine, 100 mM nonessential
aminoacids and 100 mM beta-mercaptoethanol) and B27-containing media
(Neurobasal medium, 1 X B27 and 200 mM L-glutamine supplemented with
SB431542 (10 mM), LDN193189 (100 nM) and XAV939 (10 mM) and 10 mM
Retinoic acid. On day 7 the medium was changed to N2B27 supplemented with
10 mM Retinoic acid. From day 7 until day 24 the medium (N2B27-RA) was replaced
daily.
At day 24, the neuroepithelial cells in the center of colonies that had formed neural
tube-like rosettes and were attached loosely were manually lifted, dissociated either
manually or with Accutase (Life Technologies) and then seeded on poly-L ornithine
coated micro-raft arrays or well plates in N2B27 medium overnight. The following
day, micro-rafts were released from the array and the medium was changed to N2B27
supplemented with BDNF (10 ng/ml) for all cells. For ease of understanding, days
were renumbered such that day 1 corresponded to the first day on raft arrays (Fig. 2A)
and day numbers in throughout the text use this numbering system unless otherwise
stated. Stem cell neurons on both released rafts and in wells began extending neurites
by day 2-3. Stem cell neurons were then maintained for up to 14 days post plating as
described.
Stem cell-neuron viability assay. To assess viability of H9-derived neurons, cells
were plated on either micro-raft arrays (1 million neurons/array) or in wells of a 384-
well plate (20,000 neurons/well) in N2B27 containing BDNF. Rafts were released and
transferred on day 2 as described. On either day 5 or day 14, cells were treated with
SYTOX green (1 mM; Life Technologies) and either NucBlue (2–3 drops/mL;
Molecular Probes) or DAPI (300 nM; Life Technologies) for 5–10 minutes to
visualize dead/dying cells and all cells, respectively. Neurons were then rinsed with
PBS and mounted with Fluoromount-G (Southern Biotech) for imaging and
assessment. Live neuron densities were extrapolated from the number of SYTOX-
negative neurons within a 300 mM x 300 mM image from the center of the raft or well.
To standardize neuronal density when calculating neuronal viability, percentages of
SYTOX-positive neurons were also compared from a subset of rafts or wells
containing between 100 and 300 live neurons per 300 mM x 300 mM image.
Mouse cultures. All experimental procedures were carried out in accordance with the
University of North Carolina at Chapel Hill Institutional Animal Care and Use
Committee (IACUC). Hippocampi were dissected from both postnatal day 1-3 WT-
(C57BL/6; Jackson Labs) and FMR1 knockout mice (on the C57BL/6 background;
Jackson Labs) in ice cold dissociation media (DM; containing NA2SO4 [8.2 mM],
K2SO4 [3 mM], MgCl2 [0.58 mM], CaCL2 [25.2 nM], HEPES [0.1 mM], Glucose
[0.2 mM], and phenol red [0.001%]). Hippocampi were then incubated (15 minutes
at 37uC) 2 times in 5 mL filtered Cystine-activated Papain solution (CAPS; 10 mL
DM plus: L-cystine [Sigma; 3.2 mg] and Papain [Sigma; 17units/mL]; pH 7.4). The
CAPS was replaced with DM containing 10% fetal bovine serum to inactivate papain.
Hippocampi were then washed with DM and then with Neurobasal media (NBM;
Neurobasal A media [Gibco] plus: B27 [50x; Gibco; 2%], GlutaMax [100x; Gibco,
1%], and Anti-anti [100x; Gibco, 1%]). Next, hippocampi were manually dissociated
in fresh NBM, centrifuged (67 xg) for 7 minutes at 4uC, and resuspended (12 million
neurons/mL) in NBM. Neurons were then plated on poly-D-lysine-coated raft arrays
(1 million neurons/array). Primary cortical neuron cultures from Ube3a-YFP knock-
in mice were prepared as previously described18. Rafts were then released the
following day (DIV 2) and maintained in NBM until DIV14 as described.
FM dye assays. To assess puncta-unloading rates, released rafts with either stem cell
neurons or mouse neurons were transferred via pipette to a devised micro-chamber
(8 mm diameter polydimethylsiloxane; PDMS; reservoir on a glass coverslip). Cell
culture media was replaced with HEPES-buffered solution (HBS; 119 mM NaCl,
5 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 30 mM glucose, 10 mM HEPES) and
allowed to recover for at least 30 min at 37uC. HBS was replaced with the FM dye
loading solution containing 10 mM N-(3-trimethylammoniumpropyl)-4-(6-(4-
(diethylamino)phenyl)hexatrienyl)pyridinium dibromide (FM 5-95; Invitrogen),
20 mM CNQX (Tocris Bioscience), 50 mM d-AP5 (Tocris Bioscience), and high KCl
buffered saline (90 mM KCl, 34 mM NaCl, 2 mM CaCl2, 2 mM MgCl2, 30 mM
glucose, 10 mM HEPES) for 1 min to allow for endocytosis of the dye. Loading
solution was then removed and neurons were rinsed with 10 mM FM 5-95 in HBS for
1 min. Next, neurons were rinsed three times with a high-Mg21, low-Ca21 solution
(106 mM NaCl, 5 mM KCl, 0.5 mM CaCl2, 10 mM MgCl2, 30 mM glucose, 10 mM
HEPES) containing 1 mM Advasep-7 (Biotium) for 1 min. Finally neurons were
rinsed three times with HBS containing 20 mM CNQX and 50 mM d-AP5 for 1 min.
Unloading was performed using electrical field stimulation. Positive and negative
electrodes were placed in on either side of the raft. Stimulation was generated with a
two-channel stimulus generator (STG4002; AD Instruments) in current mode with
an asymmetric waveform (2480 mA for 1 ms and 1 1600 mA for 0.3 ms) at 20 Hz
for 600 pulses. Z-stacks (.30 slices) were captured every 15 s using auto-focus for
each time-point to prevent drifting. At least five baseline images were acquired before
starting electrical stimulation.
To assess puncta volumes, neurons were loaded as described above with the fixable
version of FM 4–64 (Invitrogen) replacing FM 5–95. Following rinses, neurons were
fixed with 4% paraformaldehyde in phosphate buffered saline (PBS) containing
40 mg/ml sucrose, 1 mm MgCl2, and 0.1 mm CaCl2 for 15 minutes, rinsed 3 times
with PBS, then mounted in Fluoromount-G for imaging.
Immunocytochemistry. Neurons on rafts or in well plates were fixed with 4%
paraformaldehyde in PBS containing 40 mg/ml sucrose, 1 mm MgCl2, and 0.1 mm
CaCl2 for 20–45 min. Neurons were permeabilized in 0.25% Triton X-100 for 15 min
then blocked in PBS containing 10% goat serum for 15 min. Primary antibodies to b-
tubulin (152000; chicken; Aves Labs), MAP2 (151000; rabbit; Millipore), VGLUT1
(15200; mouse; NeuroMab), and FMRP (1510; mouse; 2F5-1 [developed by
Tartakoff, A.M./Fallon, J.R. and obtained from the Developmental Studies
Hybridoma Bank developed under the auspices of the NICHD and maintained by
The University of Iowa, Department of Biology, Iowa City, IA 52242]) were diluted in
PBS with 1% goat serum and incubated for 1 h at room temperature. AlexaFluor goat
anti-mouse, anti-rabbit, and anti-chicken antibodies conjugated to fluorophores with
488 nm, 568 nm, or 633 nm excitation wavelengths (151000; Invitrogen) were
diluted in PBS and incubated for 1 h at room temperature. Immunostaining for
neurons from Ube3a-YFP knock-in mice were performed as previously described18.
Microscopy. Images were acquired using a spinning disk confocal imaging system
(CSU-X1, Yokogawa) configured for an Olympus IX81 zero-drift microscope
(Revolution XD, Andor Technology). Light excitation was provided by 50 mW,
488 nm; 50 mW, 561 nm; and 100 mW, 640 nm lasers. The following bandpass
emission filters (BrightLine, Semrock) were used: 525/30 nm (TR-F525-030), 607/
36 nm (TR-F607-036), 685/40 nm (TR-F685-040). For FM dye imaging, we used a
spinning disk confocal imaging system with excitation at 561 nm (25% intensity) and
with the 685/40 nm emission filter. We used 232 binning to reduce the laser intensity
and acquisition time for each frame. Each z-stack was obtained in ,5 s.
Image processing and analysis. Confocal slices were sum projected in ImageJ and
converted to 8-bit depth. For the FM image analysis, we thresholded the first frame of
the z-stack to a minimum pixel value of 30. We analyzed puncta .2 pixels2 and
measured the intensity of each of these puncta throughout the registered stack. The
intensity of each puncta was normalized to the frame preceding stimulation and slope
normalized to baseline. Puncta that unloaded .5% after 1 min were classified as
‘‘unloading’’ and were included in the analysis. For puncta volume measurements, z-
stacks were analyzed using ImageJ plug-in ‘‘Foci Picker3D’’24 using the following
settings: uniform background 5, tolerance setting 5, and minimum pixels in focus 20.
Statistics. Statistical analyses were performed using GraphPad Prism. When
comparing distributions we used the non-parametric t-test (Kolmogorov-Smirnov
test). Two-tailed unpaired Student’s t test was used when comparing means for two
conditions. Error bars represented the standard error of the mean (SEM) and the
threshold for statistical significance was set at p,0.05 throughout the study.
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